Parecoxib: a shift in pain management?

References

• Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am.j Med. 107, S3–S10 (1999).
   Google Scholar
• Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann. Phatmacother 33, 979–988 (1999).
   Google Scholar
• Agency for Healthcare Policy and Research. Acute Pain Management: Operative or Medical Procedures and Trauma Clinical Practice Guideline No. 1. AHCPR Publication No. 92–0032 (February 1992).
   Google Scholar
• •Acute pain guideline.
   Google Scholar
• Arthritis Pain Guideline Panel: Simon LS, Lipman AG, Caudill-Slausberg M et al. Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. Clinical Practice Guideline. American Pain Society. American Pain Society, IL, USA (2002).
   Google Scholar
• •American Pain Society arthritis guidelines.
   Google Scholar
• Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 43,1905-1915(2000).
   Google Scholar
• •American College of Rheumatology arthritis guideline.
   Google Scholar
• Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 39, 713–722 (1996).
   PubMedGoogle Scholar
• •American College of Rheumatology arthritis guidelines.
   Google Scholar
• Bextra®(valdecoxib) tablets package insert. GD Searle LLC, NY, USA (2003).
   Google Scholar
• Celebrexe(celecoxib) capsules package insert. GD Searle LLC, NY, USA (2002).
   Google Scholar
• Vioxx®(rofecoxib) tablets package insert. Merck & Co. Inc., NJ, USA (2003).
   Google Scholar
• Talley JJ, Bertenshaw SR, Brown DL et al N-[[(5-methyl-3-phenylisoxazol-4-y1)-phenylisulfonylipropanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. j Merl Chem. 43, 1661–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 63, 33–45 (2003).
   PubMed Web of Science ®Google Scholar
• Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 61,1133–1143 (2001).
   PubMed Web of Science ®Google Scholar
• Lipsky PE, Brooks P, Crofford LJ et al Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med. 160,913-920 (2000).
   Google Scholar
• Lipsky LP, Abramson SB, Crofford L, Dubois RN, Simon LS, van de Putte LB. The classification of cyclooxygenase inhibitors. .1. Rheumatol 25,2298–2303 (1998).
   Google Scholar
• Dubois RN, Abramson SB, Crofford L et al Cyclooxygenase in biology and disease. Faseb.j 12,1063–1073 (1998).
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 43,4-13 (2000).
   Google Scholar
• Crofford U. COX-1 and COX-2 tissue expression: implications and predictions. Rheumatol 24\(Suppl. 49), 15–19 (1997).
   Google Scholar
• Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin. Arthritis Rheum. 26,21-27 (1997).
   Google Scholar
• Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal antiInflammatory drugs: do they really offer any advantages? Drugs 59, 1207–1216 (2000).
   PubMed Web of Science ®Google Scholar
• Daniels SE, Grossman EH, Kuss ME, Talwalker S, Hubbard RC. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a postoral surgery pain model. Gun. Ther. 23, 1018–1031 (2001).
   Google Scholar
• ••Double-blind trial in oral surgery.
   Google Scholar
• Karim A, Laurent A, Slater ME et al A pharmacokinetic study of intramuscular parecoxib sodium in normal subjects. Gun. Pharmacol 41,1111–1119 (2001).
   Web of Science ®Google Scholar
• Hubbard RC, Kuss M, Talwalker S. Evaluation of parecoxib, a new injectable cyclooxygenase-2-specific inhibitor, for the treatment of pain. Ann. Emerg. Merl 36, S69 (2000).
   Google Scholar
• Mehlisch DR, Desjardins PJ, Daniels S, Hubbard RC. Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery.j Otal Maxillofac. Surg: 61, 1030–1037 (2003).
   Web of Science ®Google Scholar
• ••Double-blind trial in oral surgery.
   Google Scholar
• Ott E, Nussmeier NA, Duke PC et al Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Suw. 125, 1481–1492 (2003).
   Google Scholar
• ••Double-blind trial in cardiac surgery
   Google Scholar
• Desjardins PJ, Grossman EH, Kuss ME et a/. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth. Analg. 93,721-727 (2001).
   Google Scholar
• ••Double-blind trial in oral surgery.
   Google Scholar
• Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J. Anaesth. 90,166–172 (2003).
   PubMed Web of Science ®Google Scholar
• ••Double-blind trial in orthopedic surgery.
   Google Scholar
• Rasmussen GL, Steckner K, Hogue C, Toni S, Hubbard RC. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J. Orthop. 31, 336–343 (2002).
   Google Scholar
• ••Double-blind trial in orthopedic surgery.
   Google Scholar
• Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC. Parecoxib sodium, a parenteral cyclooxygenase-2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology98, 950–956 (2003).
   PubMed Web of Science ®Google Scholar
• ••Double-blind trial in orthopedic surgery.
   Google Scholar
• Tang J, Li S, White PP et al Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 96, 1305–1309 (2002).
   PubMed Web of Science ®Google Scholar
• ••Double-blind trial in gynecological surgery.
   Google Scholar
• Barton SF, Langeland FF, Snabes MC et al Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology97, 306–314 (2002).
   PubMed Web of Science ®Google Scholar
• ••Double-blind trial in gynecological surgery.
   Google Scholar
• Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Brj Anaesth. 90, 746–749 (2003).
   Google Scholar
• ••Double-blind trial in gynecological surgery.
   Google Scholar
• Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesia'. 3,1 (2003).
   PubMedGoogle Scholar
• ••Systematic review.
   Google Scholar
• Bikhazi GB, Bajwa ZH, Snabes MC, LeComte D, Talwalker S, Hubbard RC. Parecoxib effectively treats postlaparotomy pain. Annual Meeting of the American Society for Reproductive Medicine. 481 (2001).
   Google Scholar
• Dynastat. European Public Assessment Report (CPIVfP/1166/02). The European Agency for the Evaluation of Medicinal Products. London. (2002).
   Google Scholar
• Dynastat. Summary of Product Characteristics, Pharmacia Europe EEIG. March (2002).
   Google Scholar
• Kuss M, Mehlisch D, Bauman A et al. Parecoxib vs. ketorolac: therapeutic use postoperative pain after dental surgery single-dose IV. 9th World Congress on Pain. 3–4 (1999).
   Google Scholar
• Kuss M, Mehlisch D, Bauman A et al. Analgesic activity of single IV doses of parecoxib, a COX-2 specific inhibitor and Toradol in postoperative pain. 9th World Congress on Pain 450 (1999).
   Google Scholar
• Innes C. Parecoxib: grinding away at dental pain. 9th World Congress on Pain. 7–8 (1999).
   Google Scholar
• Mehlisch D, Kuss M, Bauman A et al. Onset and duration of analgesia of single intramuscular doses of parecoxib, a COX-2 specific inhibitor and Toradol in postoperative dental pain. 9th World Congress on Pain 450–451 (1999).
   Google Scholar
• Stoltz RR, Harris SI, Kuss ME et al Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am. J. Gastroenteml 97,65–71 (2002).
   PubMed Web of Science ®Google Scholar
• ••Clinical gastrointestinal safety trial.
   Google Scholar
• Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen and placebo. Clin. Ther. 23,1422-1428 (2001).
   Google Scholar
• ••Clinical gastrointestinal safety trial.
   Google Scholar
• Goldstein JL, Talwalker S, Verburg KM et al Comparative gastroduodenal mucosal effects of valdecoxib, a potent COX-2 specific inhibitor, compared with naproxen and placebo. Presented at the 9th United European Gastroenterology Week (EUGW). Amsterdam RAI, The Netherlands, October (2001).
   Google Scholar
• Goldstein JL, Fakouhi KM, Zhao WW et al Reduced incidence of gastroduodenal ulcer with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: a multicenter trial. Presented at: Digestive Disease Week Conference. GA, USA. May (2001).
   Google Scholar
• Agrawal NM, Paperiello B, Zhao WW et al Supratherapeutic doses of valdecoxib have reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients, American College of Rheumatology 65th Annual Scientific Meeting. San Francisco, CA, USA. November (2001).
   Google Scholar
• Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther. 18,125–132 (2003).
   PubMed Web of Science ®Google Scholar
• Pavelka K, Recker DP, Verburg, KM Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxfon:1). 42,1207-1215 (2003).
   Google Scholar
• Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur. j Gastroenterol Hepatol 14,1101–1111 (2002).
   PubMed Web of Science ®Google Scholar
• Menniti-Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G, Walker AM. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other nonsteroidal anti-inflammatory drugs in Italy. Eur. j Clin. Pharmacol. 54, 393–397 (1998).
   Google Scholar
• Traversa G, Walker AM, Ippolito FM et al Gastroduodenal toxicity of different nonsteroidal anti-inflammatory drugs. Epidemiology6, 49–54 (1995).
   PubMed Web of Science ®Google Scholar
• Quigley EM, Donovan JP, Livingston WC. Ketorolac-related giant gastric ulcers. Am. J. Gastroenterol 89,631–632 (1994).
   Google Scholar
• Fuller DK, Kalekas PJ. Ketorolac and gastrointestinal ulceration. Ann. Pharmacother. 27,978–979 (1993).
   PubMed Web of Science ®Google Scholar
• McEvoy GK ATIFS Drug Information. American Society of Health System Pharmacists, MD, USA (2003).
   Google Scholar
• TOradOi (ketorolac tromethamine) injection package insert. Roche Laboratories Inc., NJ, USA (2002).
   Google Scholar
• Drugde, ;System. Hutchison TA, Shahan DR (Eds). Micromedex Inc., CO, USA (2003).
   Google Scholar
• Woywodt A, Schwarz A, Mengel M, Haller H, Zeidler H, Kohler L. Nephrotoxicity of selective COX-2 inhibitors. J. Rheumatol 28,2133–2135 (2001).
   Google Scholar
• Graham MG. Acute renal failure related to high-dose celecoxib. Ann. Intern. Med. 135, 69–70 (2001).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Lame L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Eng. I Med 343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Weir MR, Reicin A et al Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104,2280–2288 (2001).
   PubMed Web of Science ®Google Scholar
• Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac and nabumetone). Am Carrliol 89,204–209 (2002).
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAIVIA 284,1247–1255 (2000).
   Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAIVIA 286, 954–959 (2001).
   Google Scholar
• Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A. Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J. Hypertens. 21,1663-1667 (2003).
   Google Scholar
• Noveck RJ, Laurent A, Kuss M et al. Parecoxib sodium does not impair platelet function in healthy elderly and nonelderly individuals: two randomized, controlled trials. Clin. Drug Invest. 21,465-476 (2001). Clinical hematological safety trial.
   Google Scholar
• Noveck RJ, Kuss ME, Qian J et al Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirin-mediated platelet function. Region Anaesth. Pain Med. 25 (Suppl. 2), 19 (2001).
   Google Scholar
• Noveck RJ, Kuss ME, Qian J et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect heparin-mediated blood coagulation parametera. Region Anaesth. Pain Med. 26(Suppl.), 20 (2001).
   Google Scholar
• Scott LJ, Lamb HM. Rofecoxib. Drugs 58, 499–507 (1999).
   PubMed Web of Science ®Google Scholar
• Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. j Clin. Pharmacol 40,124–132 (2000).
   Google Scholar
• Lesse PT Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 inhibitor, on platelet function in the elderly. Pibbented at the European Congress of Rheumatology (EULAR). Prague, Czech Republic. (2001).
   Google Scholar
• Lesse PT, Recker D, Kuss ME. The novel COX-2 inhibitor, valdecoxib, does not affect platelet function in healthy adults. Presented at the European Congress of Rheumatology (EULAR). Prague, Czech Republic. (2001).
   Google Scholar
• Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects. Arthritis Rheum. 41,1591–1602 (1998).
   PubMed Web of Science ®Google Scholar
• Kuss HR, Talwalker S, Daniels S. Evaluation of parecoxib a new injectable cyclooxygenase-2-specific inhibitor for the treatment of pain. Ann. Emerg. Med. 36 (Suppl. 4), S69 (2000).
   Google Scholar
• Harder AT, An YH. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. J. Clin. Pharmacol 43, 807–815 (2003).
   PubMed Web of Science ®Google Scholar
• Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J. Bone Joint Surg. BE 85, 700–705 (2003).
   Google Scholar
• Dumont AS, Verma S, Dumont RJ, Hurlbert RJ. Nonsteroidal anti-inflammatory drugs and bone metabolism in spinal fusion surgery: a pharmacological quandary. J. Pharmacol. Toxicol Methods 43,31–39 (2000).
   PubMed Web of Science ®Google Scholar
• Matta JM, Siebenrock IKA. Does indomethacin reduce heterotopic bone formation after operations for acetabular fractures? A prospective randomised study. J. Bone Joint Surg. BE 79,959–963 (1997).
   PubMedGoogle Scholar
• Kjaersgaard-Andersen P, Jensen K. Cox inhibitors and bone healing. Acta Chihop. Scand 74,230–231 (2003).
   Google Scholar
• Godden D. Effects of NSAIDs on bone healing have been widely reported in maxillofacial journals. BE Med. J. 318, 1141 (1999).
   PubMed Web of Science ®Google Scholar
• Gerstenfeld LC, Thiede M, Seibert K et al. Differential inhibition of fracture healing by nonselective and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.j Orthop. Res. 21,670-675 (2003).
   Google Scholar
• Ibrahim AE, Feldman J, Karim A. Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesioltgy98, 853–861 (2003).
   Google Scholar
• Ibrahim A, Park S, Feldman J, Karim A, Kharasch ED. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesio1ogy96, 88–95 (2002).
   Google Scholar
• Ibrahim A, Karim A, Feldman J, Kharasch E. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth. Analg. 95,667-673 (2002).
   Google Scholar
• Oderda GM, Evans RS, Lloyd J et al. Cost of opioid-related adverse drug events in surgical patients. J. Pain Symptom. Manage. 25,276–283 (2003).
   PubMed Web of Science ®Google Scholar
• Ng A, Parker J, Toogood L, Cotton BR, Smith G. Does the opioid-sparing effect of rectal diclofenac following total abdominal hysterectomy benefit the patient? BE j Anaesth. 88,714–716 (2002).
   Google Scholar
• UK Medicines Information Pharmacists Group. New medicines on the market. Evaluated information for the NHS. Parecoxib. www.ukmi.nhs.uldNewMaterialsf (Accessed February 2004)
   Google Scholar
• Food and Drug Administration. Pharmacia updates Bextra label with new warnings. www.fda.govibbsitopics/ANSWERS/ 2002/ANS01170.html (Accessed February 2004)
   Google Scholar